Pregnancy outcomes of intrauterine insemination in age-matched young women according to serum anti-müllerian hormone levels

Abstract

OBJECTIVE: Serum anti-Müllerian hormone (AMH) measurements can be used to determine female fertility potential and response to treatment. The present study aimed to retrospective-ly examine the intrauterine insemination (IUI) cycles and to determine the effect of 3 levels of AMH when pregnancy was obtained in women aged ≤38 years. STUDY DESIGN: This single-center, retrospective, cohort analysis included infertile women aged <38 who underwent IUI cycles in the assisted reproductive technology center. The patients were separated into 3 groups according to AMH levels: Group I: AMH ≤1.0 ng/mL (n=207), Group II: AMH 1–5 ng/mL (n=266), and Group III: AMH ≥5.0 ng/mL (n=313). RESULTS: Baseline antral follicle count was highest in Group III (17.04±1.6, p<0.0001). The day 3 follicle-stimulating hormone (FSH) was highest in Group I (12.2±1.2, p<0.0001). An increase was determined in the pregnancy rate as the AMH level increased: Group I: 13.5%, Group II: 20.7%, and Group III: 22.4% (p= 0.031). The rates of biochemical miscarriage (p=0.866), clinical miscarriage (p=0.809), and ectopic pregnancy (p=0.932) did not differ in terms of the AMH level. There was no significant difference between the groups in respect to reproductive outcomes. CONCLUSION: The pregnancy rate and the baseline antral follicle count increased with increasing AMH levels irrespective of age. (J Reprod Med 2021,66:195–202). © 2021 Elsevier B.V., All rights reserved.